{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:51:32Z","timestamp":1757703092853},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/ico.0b013e3181cb83f2","type":"journal-article","created":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T00:01:48Z","timestamp":1317772908000},"page":"1273-1276","source":"Crossref","is-referenced-by-count":3,"title":["Histologic Findings of Bevacizumab-Treated Human Conjunctiva in Stevens\u2013Johnson Syndrome"],"prefix":"10.1097","volume":"30","author":[{"given":"Harvey S","family":"Uy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen N","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex S","family":"Sua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210204","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","article-title":"Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R2-17-20210204","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1167\/iovs.01-1277","article-title":"VEGF-dependent conjunctivalization of the corneal surface.","volume":"44","author":"Joussen","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R3-17-20210204","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization.","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R4-17-20210204","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","article-title":"Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome.","volume":"27","author":"Uy","year":"2008","journal-title":"Cornea"},{"key":"R5-17-20210204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-17-20210204","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization.","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R7-17-20210204","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ICO.0b013e3181822615","article-title":"Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium.","volume":"28","author":"Wu","year":"2009","journal-title":"Cornea"},{"key":"R8-17-20210204","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R9-17-20210204","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/IAE.0b013e3181619bee","article-title":"Roca JA, et al; Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.","volume":"28","author":"Wu","year":"2008","journal-title":"Retina"},{"key":"R10-17-20210204","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/IAE.0b013e318176de48","article-title":"Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.","volume":"28","author":"Kook","year":"2008","journal-title":"Retina"},{"key":"R11-17-20210204","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00417-008-0856-x","article-title":"A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports).","volume":"246","author":"Torres-Soriano","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R12-17-20210204","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study.","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R13-17-20210204","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/ICO.0b013e31802eb264","article-title":"Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.","volume":"26","author":"Chang","year":"2007","journal-title":"Cornea"},{"key":"R14-17-20210204","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","article-title":"Analysis of the acute ophthalmic manifestations of the erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysis disease spectrum.","volume":"102","author":"Power","year":"1995","journal-title":"Ophthalmology"},{"key":"R15-17-20210204","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.ico.0000611440.32234.8f","article-title":"Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.","volume":"27","author":"Carrasco","year":"2008","journal-title":"Cornea"},{"key":"R16-17-20210204","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"R17-17-20210204","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"},{"key":"R18-17-20210204","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","article-title":"Subconjunctival bevacizumab for vascularized rejected corneal grafts.","volume":"33","author":"Awadein","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"R19-17-20210204","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3928\/1542-8877-20060301-12","article-title":"Needle bleb revision of encapsulated filtering bleb with bevacizumab.","volume":"37","author":"Kahook","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R20-17-20210204","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R21-17-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R22-17-20210204","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":"Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R23-17-20210204","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/ICO.0b013e318160d019","article-title":"Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.","volume":"27","author":"Hurmeric","year":"2008","journal-title":"Cornea"},{"key":"R24-17-20210204","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/bjo.2006.108795","article-title":"Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin).","volume":"91","author":"Gibran","year":"2007","journal-title":"Br J Ophthalmol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003226-201111000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:45:09Z","timestamp":1618278309000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201111000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e3181cb83f2","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}